Understanding COPD and cardiovascular disease in Greece
The HELlenic Thoracic Society Initiative for CΟPD and CVD
Hellenic Thoracic Society · NCT06595784
This study is trying to learn more about people in Greece who have both COPD and heart disease to see how these conditions affect their lives and healthcare needs over two years.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 900 (estimated) |
| Ages | 35 Years to 99 Years |
| Sex | All |
| Sponsor | Hellenic Thoracic Society (other) |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 2 sites (Alexandroupoli and 1 other locations) |
| Trial ID | NCT06595784 on ClinicalTrials.gov |
What this trial studies
This observational study aims to gather comprehensive data on patients suffering from Chronic Obstructive Pulmonary Disease (COPD) and cardiovascular diseases (CVD) in Greece. It will document the demographic and clinical characteristics of this population, track COPD- and CVD-related adverse events over a two-year period, and assess their quality of life and healthcare resource utilization. The study is coordinated by the Hellenic Thoracic Society and involves multiple centers across Greece.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 35 years old diagnosed with COPD and at least one cardiovascular comorbidity.
Not a fit: Patients without any cardiovascular comorbidity or those with active malignancies or planned surgeries may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for patients with COPD and CVD, enhancing their quality of life.
How similar studies have performed: While similar studies have been conducted, this specific initiative focuses on a unique population in Greece, making it a novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria Patients should cumulatively meet the following three (3) criteria to be enrolled in the study: 1. To have been diagnosed with chronic obstructive pulmonary disease and at least one cardiovascular comorbidity (heart failure, atherosclerotic cardiovascular disease, atrial Fibrillation, severe valvular disease) 2. Adults aged \>35 years at the time of inclusion in the study, 3. With signed informed consent for their participation in the study. Exclusion criteria Patients with the below limitations are not eligible to participate in the study Patients: 1. Without at least one cardiovascular comorbidity, 2. With history of lung cancer 3. With any other active malignancy and undergoing treatment (chemotherapy/radiotherapy/immunotherapy) 4. With any thoracic or abdominal surgery planned during study follow-up period 5. With participation in any COPD-related interventional study at study entry or during study duration. 6. Without signed informed consent for their participation in the study.
Where this trial is running
Alexandroupoli and 1 other locations
- Department of Respiratory Medicine, Medical School, Democritus University of Thrace, University General Hospital — Alexandroupoli, Greece (RECRUITING)
- 5th Pulmonary Department, "Sotiria" Chest Diseases Hospital, Athens, Greece — Athens, Greece (RECRUITING)
Study contacts
- Principal investigator: Georgios Hillas — 5th Pulmonary Department, "Sotiria" Chest Diseases Hospital, Athens, Greece
- Study coordinator: Stylianos Loukides
- Email: loukstel@med.uoa.gr
- Phone: +306944380549
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Chronic Obstructive Pulmonary Disease, Cardiovascular Diseases, Chronic obstructive pulmonary disease, COPD, Cardiovascular disease, CVD, Protocol, Real-World Data